SecBot SecBot
8-K ·Filed Apr 30, 2026

PCRX

Pacira BioSciences, Inc.
NEUTRAL
Impact 4/10
Horizonweeks Processed6mo ago SEC0001628280-26-028854
8-K Item 2.02: Earnings release
Actionable Insight • Neutral

With guidance unchanged and no major catalysts near-term, the stock is likely range-bound. Key catalysts to watch: ZILRETTA shoulder OA Phase 3 topline (H2 2026) and PCRX-201 Phase 2 Part A readout. The aggressive buyback ($50M in Q1) provides a floor but does not offset declining GAAP earnings. Monitor for any guidance revision on the Q2 call.

DirectionNeutral
Confidencehigh
Horizonweeks

How the stock moved after the report

NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$24.44
T+0 close · Apr 30, 2026 · via day close
Latest settled
+9.70%
T+60 · $26.81
Vs SPY
+6.63%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · May 1 $24.44entry
  2. T+1 · 7mo ago +1.02%α +1.36% · $24.69
  3. T+5 · 6mo ago −5.28%α −7.63% · $23.15
  4. T+20 · 6mo ago −6.06%α −11.32% · $22.96
  5. T+60 · 4mo ago +9.70%α +6.63% · $26.81

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Pacira BioSciences reported Q1 2026 revenue of $177.4M (+5% YoY) and GAAP EPS of $0.07, down from $0.10 a year ago. Non-GAAP EPS was $0.60, roughly in line with the $0.62 Street consensus from the prior quarter. The company reiterated full-year 2026 guidance, completed enrollment in a pivotal ZILRETTA shoulder OA study, and repurchased $50M in stock. Results were solid but not exceptional, revenue growth was steady, but GAAP profitability declined and guidance was unchanged.

Key Financial Metrics

EPS
$0.07
Revenue
$177.4M
+5.0% YoY
Rating
in line
Guidance
$745M-$770M
maintained
Gross Margin
79%

Key Facts

  • Q1 2026 total revenue of $177.4M, up 5% YoY from $168.9M
  • GAAP net income of $2.9M ($0.07 per share) vs $4.8M ($0.10) in Q1 2025
  • Non-GAAP net income of $24.5M ($0.60 per share) vs $30.0M ($0.62) in Q1 2025
  • Adjusted EBITDA of $40.2M vs $44.1M in Q1 2025
  • EXPAREL sales $143.3M (+5% YoY); ZILRETTA $26.8M (+15%); iovera $6.2M (+21%)
  • Repurchased 2.2M shares for $50M at avg $22.28; $100M remaining on authorization
  • Full-year 2026 guidance reiterated: total revenue $745M-$770M, EXPAREL $600M-$620M
  • Completed enrollment in Phase 3 ZILRETTA shoulder OA study; topline expected by year-end
  • Cash and investments of $202.2M at quarter-end

Financial Impact

Revenue grew 5% YoY but GAAP net income fell 39% YoY; non-GAAP EPS roughly flat vs prior year

revenueepsebitda

Risk Factors

  • GAAP net income declining YoY despite revenue growth, operating expenses rising faster
  • EXPAREL faces generic competition risk and GPO discounting pressure
  • Pipeline catalysts (ZILRETTA shoulder, PCRX-201) are binary and may not materialize

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
69% bullish (13 analysts)

Investment Themes

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001628280-26-028854
Document: pcrx-20260430.htm0001628280-26-028854
Document: 0001628280-26-028854-index-headers.html0001628280-26-028854
Document: 0001628280-26-028854-index.html0001628280-26-028854
Document: 0001628280-26-028854.txt0001628280-26-028854
8-K Data (Synthetic)0001628280-26-028854

Track record

29 reports on PCRX

Performance horizon

5 of 7 bullish or bearish reports moved the stock their way by T+20. Best: +42.26% at T+60 after the Aug 6, 2026 report. 8 of 9 went positive at some point.

Filters
  1. Nov 12, 20264d ago 8-K Bearish 6/10 Entry $36.46 Now $36.48 −0.05% settles Dec 14
  2. Nov 12, 20264d ago SC TO-T/A Mixed 7/10 Entry $36.46 Now $36.48 +0.05% settles Dec 14
  3. Nov 12, 20264d ago SC 14D-9/A Neutral 3/10 Entry $36.46 Now $36.48 +0.05% settles Dec 14
  4. Nov 5, 202611d ago 8-K Neutral 5/10 Entry $36.43 Now $36.48 +0.14% settles Dec 7
  5. Nov 3, 202613d ago SC 14D-9/A Neutral 3/10 Entry $36.40 Now $36.48 +0.22% settles Dec 3
  6. Oct 30, 202617d ago SC 13G/A Neutral 2/10 Entry $36.39 Now $36.48 +0.25% settles Nov 30
  7. Oct 30, 202617d ago SC 14D-9 Bullish 7/10 Entry $36.39 Now $36.48 +0.25% settles Nov 30
  8. Oct 30, 202617d ago SC TO-T Mixed 7/10 Entry $36.39 Now $36.48 +0.25% settles Nov 30
  9. Oct 13, 20264w ago SC 13D/A Bearish 7/10 Entry $36.40 to $36.46 Now $36.48 −0.22% ▼ −0.16% −1.44% vs SPY
  10. Oct 8, 20265w ago SC TO-C Bullish 7/10 Entry $36.31 to $36.43 Now $36.48 +0.47% ▲ +0.33% +5.89% vs SPY
Showing 10 of 29

US Market Status

Market Closed · Opens in 7h 3m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Apr 30, 2026